Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes AI

The Future of Longevity: AI and Nanorobots to Radically Extend Life

by Team Lumida
June 25, 2024
in AI, Health and Longevity
Reading Time: 3 mins read
A A
0
person holding black and white microscope

Photo by Jaron Nix on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

  1. AI-driven drug discovery could drastically cut down clinical trial times.
  2. Medical nanorobots may revolutionize immune systems by the 2030s.
  3. By 2040s, mind-backup systems might allow near-immortality.

What Happened?

Futurist Ray Kurzweil claims that AI will revolutionize drug discovery and medical interventions by the end of the 2020s. He believes biological simulators will soon generate crucial safety and efficacy data in hours, not years.

This shift could lead to faster drug approvals and save countless lives. Kurzweil also predicts that medical nanorobots will emerge in the 2030s, vastly enhancing our immune systems and treating metabolic diseases. By 2040s, he envisions mind-backup systems that could essentially render death obsolete.

Why It Matters?

These advancements could disrupt traditional medical models and extend human lifespans dramatically. Faster drug approvals would mean quicker access to lifesaving treatments. Medical nanorobots could address diseases that our natural immune systems can’t, such as cancer and neurodegenerative disorders.

The potential to back up our minds might lead to radical life extension, fundamentally changing the concept of mortality. Investors should note the profound implications for the healthcare and biotech sectors, which could experience exponential growth.

What’s Next?

Expect increased investment in AI-driven pharmaceutical research and biotech firms focused on nanotechnology. Regulatory landscapes will evolve to accommodate simulated trials, despite potential bureaucratic resistance. By the mid-2040s, mind-backup technologies will likely face ethical and security challenges, but Kurzweil is optimistic about overcoming these hurdles.

As these technologies become mainstream, they will likely follow the trajectory of the cell phone—starting expensive and exclusive, but eventually becoming widely accessible.

Source: Fortune Well
Tags: AI-driven drug discoverymedical nanorobotsmind-backup systemsRay Kurzweil
Previous Post

Bitcoin Crashes to $62K: What’s Behind the $150M Liquidation?

Next Post

TikTok Ban Could Dent Oracle’s Earnings: What Investors Need to Know

Recommended For You

Anthropic’s Newest AI Is Rattling Some Enterprise Customers

by Team Lumida
18 hours ago
Pentagon–Anthropic Feud Escalates as AI Policy Clash Threatens Defense Contracts

Bloomberg Opinion's Parmy Olson reports that Anthropic's latest Claude models are making some business customers uncomfortable — raising questions about AI personality, autonomy, and who is really in...

Read more

Nvidia AI Chips Were Smuggled to China Through Japan, Taiwan Suspects

by Team Lumida
18 hours ago
Nvidia’s Stock: Is It Too Good to Be True Now?

Taiwan prosecutors say at least one shipment of Nvidia-powered Super Micro servers cleared customs and traveled via Japan to Hong Kong — a known waypoint for hardware ultimately...

Read more

SK Hynix and Micron Cross $1 Trillion — AI Memory Is the New Bottleneck

by Team Lumida
18 hours ago
SK Hynix and Micron Cross $1 Trillion — AI Memory Is the New Bottleneck

SK Hynix surged 13% to join the $1 trillion club, with Micron up 19% the day before — as investors price in a multi-year HBM shortage that gives...

Read more

The First AI-Native Graduating Class Is Entering the Workforce — Into a Market That Both Wants and Fears Them

by Team Lumida
2 days ago
China’s AI Startups Challenge Global Leaders Amid U.S. Trade Curbs

The Class of 2026 started college months before ChatGPT launched and is leaving as AI reshapes the entry-level jobs they expected to land. Employers are split: some are...

Read more

Pope Leo XIV Issues Landmark AI Encyclical — Calls to ‘Disarm’ Technology Before It Dominates Humanity

by Team Lumida
3 days ago
Pope Leo XIV Issues Landmark AI Encyclical — Calls to ‘Disarm’ Technology Before It Dominates Humanity

In his most consequential act since becoming pope, Leo XIV released 'Magnifica humanitas,' a sweeping moral directive on artificial intelligence that puts the Catholic Church on a collision...

Read more

Weight-Loss Drugs Like Ozempic May Also Slow Cancer — Four New Studies Show Striking Results

by Team Lumida
6 days ago
Eli Lilly and Novo Nordisk Shares Plunge Amid Ozempic Vision Loss Fears

GLP-1 drugs used for diabetes and obesity are linked to reduced tumor progression, lower cancer mortality, and decreased breast cancer risk across hundreds of thousands of patients in...

Read more

Nvidia Posts $81.6 Billion Quarter — Up 85% — as the Agentic AI Era Goes Parabolic

by Team Lumida
7 days ago
Nvidia’s AI Demand Surge: Hon Hai Ramps Up Server Production

Nvidia shattered expectations with record Q1 revenue of $81.6 billion and net income of $58.3 billion, driven by exploding demand for AI agents and data-center compute. CEO Jensen...

Read more

Anthropic Is on Pace for Its First Profitable Quarter — With $10.9 Billion in Q2 Revenue

by Team Lumida
7 days ago
Pentagon–Anthropic Feud Escalates as AI Policy Clash Threatens Defense Contracts

Anthropic expects $10.9 billion in Q2 revenue — more than double Q1 — and $559 million in operating profit, its first profitable quarter ever, driven by explosive enterprise...

Read more

OpenAI Is Filing for Its IPO — Possibly as Soon as This Friday

by Team Lumida
1 week ago
OpenAI Hack: Why AI Companies Are Prime Targets for Cyberattacks

OpenAI is working with Goldman Sachs and Morgan Stanley on a confidential IPO filing it could submit as early as Friday, targeting a public debut as soon as...

Read more

Meta’s 8,000 Layoffs Are Underway — and It’s Already Tracking Employee Keystrokes to Train AI

by Team Lumida
1 week ago
a white square with a blue logo on it

Meta began cutting roughly 8,000 jobs Wednesday while simultaneously moving 7,000 workers into AI roles — the most sweeping restructuring in the company's history, funded by eliminating positions...

Read more
Next Post
a red cube with white text

TikTok Ban Could Dent Oracle's Earnings: What Investors Need to Know

a person holding a phone

AI and Crypto Shakeup: Nvidia and Bitcoin's Massive Drops Explained

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Oil Prices Surge: What Falling US Crude Stocks Mean for Your Investments

Oil Slides as Markets Weigh Ukraine Diplomacy and OPEC+ Supply Decisions

November 27, 2025
woman in gray hoodie sweater jogging

This 55-Year-Old’s Simple Routine Beats Millionaires at Anti-Aging

May 17, 2024
a computer keyboard with a blue light on it

Chinese AI Breakthrough Sends Global Chip Stocks into Tailspin

January 27, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018